PE20061398A1 - Vacuna de toxoide de c. perfringens alfa - Google Patents

Vacuna de toxoide de c. perfringens alfa

Info

Publication number
PE20061398A1
PE20061398A1 PE2006000396A PE2006000396A PE20061398A1 PE 20061398 A1 PE20061398 A1 PE 20061398A1 PE 2006000396 A PE2006000396 A PE 2006000396A PE 2006000396 A PE2006000396 A PE 2006000396A PE 20061398 A1 PE20061398 A1 PE 20061398A1
Authority
PE
Peru
Prior art keywords
vaccine
perfringens
antigens
sources
alpha toxoid
Prior art date
Application number
PE2006000396A
Other languages
English (en)
Inventor
Huchappa Jayappa
Kevin O'connell
Original Assignee
Schering Plough Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36820082&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20061398(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Plough Ltd filed Critical Schering Plough Ltd
Publication of PE20061398A1 publication Critical patent/PE20061398A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0258—Escherichia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)

Abstract

REFERIDA A UNA VACUNA QUE COMPRENDE UN ANTIGENO SELECCIONADO DE UN TOXOIDE ALFA DE CLOSTRIDIUM PERFRINGENS, UN FRAGMENTO ANTIGENICO DE UN TOXOIDE ALFA DE C. PERFRINGENS, UN FRAGMENTO ANTIGENICO INACTIVO DE UNA TOXINA ALFA DE C. PERFRINGENS Y COMBINACIONES DE LOS MISMOS. LA VACUNA TAMBIEN PUEDE CONTENER UNO O MAS ANTIGENOS BACTERIANOS, VIRALES O PARASITARIOS. LAS FUENTES DE LOS ANTIGENOS VIRALES SON EL VIRUS DE LA ENFERMEDAD DE BURSITIS INFECCIOSA, VIRUS DE LA BRONQUITIS INFECCIOSA, REOVIRUS Y VIRUS DE LA ENFEREDAD DE NEWCASTLE; LAS FIENTES DE LOS ANTIGENOS BACTERIANOS SON E. COLI, SALMONELLA Y CAMPYLOBACTER Y LAS FUENTES DE LOS ANTIGENOS PARASITARIOS SON DE EIMERIA. DICHA VACUNA ES UTIL PARA LA PROTECCION DE ANIMALES CONTRA ENFERMEDADES CLOSTRIDIALES
PE2006000396A 2005-04-18 2006-04-17 Vacuna de toxoide de c. perfringens alfa PE20061398A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US67228905P 2005-04-18 2005-04-18

Publications (1)

Publication Number Publication Date
PE20061398A1 true PE20061398A1 (es) 2007-01-15

Family

ID=36820082

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2006000396A PE20061398A1 (es) 2005-04-18 2006-04-17 Vacuna de toxoide de c. perfringens alfa

Country Status (25)

Country Link
US (2) US8980283B2 (es)
EP (1) EP1874344B1 (es)
JP (2) JP5243951B2 (es)
KR (1) KR20080005277A (es)
CN (1) CN101198352B (es)
AR (1) AR054251A1 (es)
AU (1) AU2006236365B2 (es)
BR (1) BRPI0610843B1 (es)
CA (1) CA2606180C (es)
CR (1) CR9443A (es)
DK (1) DK1874344T3 (es)
ES (1) ES2583484T3 (es)
IL (1) IL186701A0 (es)
MA (1) MA29406B1 (es)
MX (1) MX2007013053A (es)
MY (1) MY149604A (es)
NZ (1) NZ562637A (es)
PE (1) PE20061398A1 (es)
RU (1) RU2434638C2 (es)
SG (1) SG186672A1 (es)
TN (1) TNSN07387A1 (es)
TW (1) TWI311057B (es)
UA (1) UA98099C2 (es)
WO (1) WO2006113772A1 (es)
ZA (1) ZA200709516B (es)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY149604A (en) * 2005-04-18 2013-09-13 Schering Plough Ltd C.perfringens alpha toxoid vaccine
PL2004220T3 (pl) * 2006-03-30 2015-11-30 Zoetis Services Llc Sposoby i kompozycje do szczepienia drobiu
EP2007420B1 (en) * 2006-04-17 2013-03-06 Intervet International B.V. Recombinant attenuated clostridium organisms and vaccine
CN101578109A (zh) 2006-10-27 2009-11-11 陶氏益农公司 用于坏死性肠炎的、包含突变的产气荚膜梭菌α毒素抗原的家禽疫苗及生产疫苗的方法
KR20090081389A (ko) * 2006-11-20 2009-07-28 인터벳 인터내셔널 비.브이. 백신의 제조를 위한 클로스트리디움 퍼프린젠스 ｃ 형 박테리아의 용도
US7820171B2 (en) * 2007-04-12 2010-10-26 Pradip Maiti Use of avian anti-methanogen antibodies for reduction of methane production
CA2685533C (en) 2007-06-22 2019-07-02 University Of Guelph Vaccine against clostridium perfringens
WO2009076668A2 (en) * 2007-12-13 2009-06-18 Alpharma, Inc. Bacteriophage preparations and method of use thereof
US8277650B2 (en) 2009-03-13 2012-10-02 Terrasep, Llc Methods and apparatus for centrifugal liquid chromatography
WO2011103465A2 (en) * 2010-02-20 2011-08-25 Alexey Gennadievich Zdanovsky Botulinum neurotoxin antigenic compositions and methods
WO2011151941A1 (ja) * 2010-06-04 2011-12-08 国立大学法人東京大学 制御性ｔ細胞の増殖または集積を誘導する作用を有する組成物
CN102008720B (zh) * 2010-07-20 2015-02-25 东北农业大学 抗魏氏梭菌病转基因植物疫苗及其制作方法
US20140377248A1 (en) * 2011-12-23 2014-12-25 Merz Pharma Gmbh & Co. Kgaa Method for the manufacturing of di-chain proteins for use in humans
CN102657683B (zh) * 2012-06-02 2014-05-07 哈尔滨工业大学 一种免疫类毒素的制备方法
CN102698259B (zh) * 2012-06-12 2017-02-08 北京中海生物科技有限公司 一种鸡坏死性肠炎（a型）灭活疫苗制备方法
CN102688484B (zh) * 2012-06-13 2016-03-30 北京中海生物科技有限公司 一种鸡坏死性肠炎（c型）灭活疫苗的生产方法
ES2759583T3 (es) 2012-10-26 2020-05-11 Intervet Int Bv Vacunas de Salmonella de protección cruzada
CN103463632B (zh) * 2013-09-05 2016-01-06 山东农业大学 牛羊肠毒血症的d型产气荚膜梭菌类毒素疫苗的制备方法
FR3012964A1 (fr) * 2013-11-12 2015-05-15 Seppic Sa Vaccins adjuves pour vaccination aviaire in ovo
CN103861094A (zh) * 2014-03-27 2014-06-18 山东农业大学 一种产气荚膜梭菌α毒素基因工程疫苗及其应用
CN104131022A (zh) * 2014-08-01 2014-11-05 中国农业科学院兰州兽医研究所 产气荚膜梭菌α、β1、β2、ε毒素共表达载体及其构建方法和表达方法
CN104531730B (zh) * 2014-12-15 2018-07-17 中国人民解放军军事医学科学院军事兽医研究所 产气荚膜梭菌α毒素人源化单链抗体8B
CN104531731B (zh) * 2014-12-15 2018-06-26 中国人民解放军军事医学科学院军事兽医研究所 产气荚膜梭菌α毒素人源化单链抗体7D
CN104531867B (zh) * 2014-12-25 2017-03-29 湖北省农业科学院畜牧兽医研究所 产气荚膜梭菌肠毒素阳性菌双重荧光定量pcr快速检测试剂盒
EP3112474A1 (en) * 2015-06-29 2017-01-04 Evonik Degussa GmbH Method of detecting avian necrotic enteritis
BR112019015140A2 (pt) 2017-01-23 2020-04-14 Univ Florida indução de imunidade protetora contra antígenos
JP7161729B2 (ja) * 2017-02-28 2022-10-27 一般財団法人阪大微生物病研究会 多価ワクチン
JP2020527051A (ja) * 2017-05-31 2020-09-03 ハー マジェスティー ザ クイーン イン ライト オブ カナダ アズ リプレゼンティッド バイ ザ ミニスター オブ アグリカルチャー アンド アグリ−フードＨｅｒ Ｍａｊｅｓｔｙ Ｔｈｅ Ｑｕｅｅｎ Ｉｎ Ｒｉｇｈｔ Ｏｆ Ｃａｎａｄａ Ａｓ Ｒｅｐｒｅｓｅｎｔｅｄ Ｂｙ Ｔｈｅ Ｍｉｎｉｓｔｅｒ Ｏｆ Ａｇｒｉｃｕｌｔｕｒｅ Ａｎｄ Ａｇｒｉ−Ｆｏｏｄ 家禽における壊疽性腸炎に対するワクチン
EP3634480A1 (en) * 2017-06-09 2020-04-15 Hipra Scientific, S.L.U. Vaccine comprising clostridium toxoids
BR112020002374A2 (pt) * 2017-08-04 2020-09-08 University Of Florida Research Foundation, Incorporated indução de imunidade protetora contra antígenos
CN107596361B (zh) * 2017-09-12 2020-08-14 浙江海隆生物科技有限公司 牛a型产气荚膜梭菌的亚单位疫苗及其制备方法和应用
CN107875377B (zh) * 2017-11-06 2020-01-03 山东农业大学 一种e型产气荚膜梭菌类毒素疫苗的制备方法
CN109954135B (zh) * 2017-12-25 2023-01-31 金宇保灵生物药品有限公司 牛a型产气荚膜梭菌灭活类毒素疫苗及其制备方法
CN108578686B (zh) * 2018-04-23 2022-07-01 杨凌凯瑞生物科技有限公司 一种制备羊梭菌病基因工程亚单位疫苗的方法
CN109111509B (zh) * 2018-09-19 2021-08-13 天康制药(苏州)有限公司 腐败梭菌α毒素突变体、表达其的基因、制备方法和腐败梭菌疫苗
CN111500482B (zh) * 2019-01-31 2023-09-05 内蒙古金宇保灵生物技术研究院有限公司 一种羊a型产气荚膜梭菌菌株及其灭活疫苗和疫苗制备方法
CN109943507B (zh) * 2019-03-26 2021-08-17 中国兽医药品监察所 一种兽用a型产气荚膜梭菌类毒素的制备方法及其应用
CN110041437B (zh) * 2019-04-29 2020-12-25 中国兽医药品监察所 一种无毒性破伤风毒素和诺维梭菌α毒素重组融合蛋白

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2257230B1 (es) 1973-09-14 1976-11-19 Agronomique Inst Nat Rech
SU627611A1 (ru) * 1977-09-30 1980-02-05 В.П. Землякова Вакцинный препарат в.п. земл ковой против клостридиозов животных и птиц
GB2283020B (en) 1992-05-20 1996-05-01 Secr Defence Clostridium perfringens vaccines
EP0692974B2 (en) * 1993-03-29 2007-05-30 Pfizer Inc. Multicomponent clostridial vaccines using saponin adjuvants
US6048535A (en) 1997-06-12 2000-04-11 Regents Of The University Of Minnesota Multivalent in ovo avian vaccine
US7250286B2 (en) 2002-05-21 2007-07-31 Schering-Plough Corporation Methods for the in vitro culture of Sporozoea sp. and uses thereof
WO2005002509A2 (en) * 2003-06-09 2005-01-13 Corixa Corporation Dna vectors
WO2005016383A1 (en) * 2003-08-14 2005-02-24 Merial Limited Compositions and vaccines containing antigen(s) of cryptosporidium parvum and of another pathogen
WO2006041933A2 (en) * 2004-10-05 2006-04-20 Diversa Corporation Improved vaccines
MY149604A (en) * 2005-04-18 2013-09-13 Schering Plough Ltd C.perfringens alpha toxoid vaccine
KR20090081389A (ko) 2006-11-20 2009-07-28 인터벳 인터내셔널 비.브이. 백신의 제조를 위한 클로스트리디움 퍼프린젠스 ｃ 형 박테리아의 용도

Also Published As

Publication number Publication date
UA98099C2 (uk) 2012-04-25
CR9443A (es) 2008-02-20
BRPI0610843A2 (pt) 2010-07-27
JP2012062330A (ja) 2012-03-29
KR20080005277A (ko) 2008-01-10
US20060233825A1 (en) 2006-10-19
JP2008536936A (ja) 2008-09-11
JP5243951B2 (ja) 2013-07-24
MA29406B1 (fr) 2008-04-01
US9662380B2 (en) 2017-05-30
US8980283B2 (en) 2015-03-17
MY149604A (en) 2013-09-13
MX2007013053A (es) 2008-01-14
WO2006113772A1 (en) 2006-10-26
BRPI0610843B1 (pt) 2021-11-30
AU2006236365A1 (en) 2006-10-26
RU2007142337A (ru) 2009-05-27
NZ562637A (en) 2010-06-25
TWI311057B (en) 2009-06-21
US20150140033A1 (en) 2015-05-21
CN101198352B (zh) 2011-07-27
TNSN07387A1 (en) 2009-03-17
SG186672A1 (en) 2013-01-30
CA2606180C (en) 2016-09-13
ZA200709516B (en) 2008-11-26
CA2606180A1 (en) 2006-10-26
AR054251A1 (es) 2007-06-13
DK1874344T3 (en) 2016-09-19
EP1874344A1 (en) 2008-01-09
EP1874344B1 (en) 2016-06-08
AU2006236365B2 (en) 2012-02-02
IL186701A0 (en) 2008-02-09
ES2583484T3 (es) 2016-09-21
TW200719910A (en) 2007-06-01
CN101198352A (zh) 2008-06-11
RU2434638C2 (ru) 2011-11-27

Similar Documents

Publication Publication Date Title
PE20061398A1 (es) Vacuna de toxoide de c. perfringens alfa
CO2022013525A2 (es) Anticuerpos contra sars-cov-2 y métodos para usarlos
CL2022003085A1 (es) Anticuerpos contra sars-cov-2
CY1120015T1 (el) Μεθοδοι χορηγησης εμβολιων
AR068507A1 (es) Construcciones vector fluorocarbonado-antigeno para el suministro de antigenos ifluenza
PH12019501766A1 (en) Porcine coronavirus vaccines
AR121361A1 (es) Vacuna
MX2022003435A (es) Desarrollo de una vacuna novedosa atenuada viva contra la peste porcina africana basada en la eliminacion del gen i177l.
CO6361948A2 (es) Uso de antigeno de mycoplasma bovis
CO6210756A2 (es) La proteina linfopoyetina estromal timica canina y usos de la misma
CO2021010786A2 (es) Toxinas apxia, apxiia y apxiiia inactivadas
CL2021002727A1 (es) Vacuna con subunidades del vfpc
EA201990010A1 (ru) Вакцина против вируса инфекционного бронхита
GEP201706766B (en) Methods and compositions for vaccinating against staphylococcus aureus
BR112023006274A2 (pt) Proteína de fusão útil para vacinação contra rotavírus
CO2021005066A2 (es) Vacuna de ibv 4/91 con proteína espicular heteróloga
CL2008003845A1 (es) Vacuna que comprende una emulsion, una bacterina tratada termicamente a 55-70°c por 5-10 horas, que comprende una suspension de bacterias muertas de la especie leptospira bratislava, y de 1 a 13 virus causantes de enfermedad porcina.
AR047581A1 (es) Vacunas de calicivirus felino
BR112018015912A2 (pt) vírus da vacina da síndrome respiratória e reprodutiva porcina
BR0315980A (pt) Antìgenos p153 e p156 para o diagnóstico imunológico da ehrlichiose canina e humana e uso dos mesmos
CL2009000287A1 (es) Composicion que comprende un alfavirus salmonideo (sav) inactivado y al menos un componente seleccionado de una bacteria muerta/inactivada, otro virus inactivado, un hongo, un parasito y un material antigenico derivado de la bacteria, virus, hongo o parasito anterior; metodo para elaborar la composicion y uso del sav.
EP4349367A3 (en) A vaccine for protection against streptococcus suis
CO2021005069A2 (es) Vacuna de ibv h52 con proteína espicular heteróloga
AR048429A1 (es) Aislados antigenicos y vacunas del virus de la bursitis infecciosa
Walker et al. Opportunities and strategies to further reduce animal use for Leptospira vaccine potency testing

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed